

Date: 13/08/2018

To
Deputy Manager
Dept. of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Fort, MUMBAI - 400001

Sub: Outcome of Board Meeting held on 13th August, 2018.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 13th August, 2018 has approved Unaudited financial results for the quarter ended on 30th June, 2018. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Unaudited Financial results for the quarter ended 30th June, 2018 along with Limited Review Report issued by the Statutory Auditors of the company.

The Meeting started at 5.00 PM and ended at 7:05 PM

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited



M Kalyan Ram
Whole Time Director
DIN: 02012580

Statement of Unaudited Financial Results for the Quarter ended on 30th June,2018					Rs.in Lakhs
S.No.	PARTICULARS	QUARTER ENDED			Year Ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		Un-audited	Audited	Un-audited	Audited
I	Revenue from operations				
II	Other income	1,358.30	1,232.96	1,096.33	4,700.12
III	Total Income	0.46	0.61	12.74	13.35
IV	Expenses	1,358.76	1,233.57	1,109.07	4,713.47
	a) (Increase)/decrease in stock in trade and WIP				
	b) Consumption of Raw materials	(60.41)	90.37	(338.26)	(302.77)
	c) Purchase of traded goods	-	-	-	-
	d) Employees Cost	356.60	326.03	407.47	1,259.60
	e) Depreciation and amortisation	206.77	173.45	219.90	758.52
	f) Finance Cost	115.98	92.02	115.68	463.94
	g)Administrative Expenditure	66.41	61.84	48.64	236.75
	Total	493.86	377.27	575.02	1,896.64
V	Profit before Exceptional and Extraordinary Items and Tax	1,179.22	1,120.98	1,028.45	4,312.68
VI	Exceptional items	179.54	112.60	80.62	400.78
VII	Profit before Extraordinary Items and Tax	-	-	-	-
VIII	Extraordinary Items	179.54	112.60	80.62	400.78
IX	Profit before tax	-	-	-	-
X	Tax Expense	179.54	112.60	80.62	400.78
	a. Current Tax				
	b. Deffered tax	34.54	55.50	15.36	110.42
XI	Profit for the Period from continuing activities	(4.13)	(22.98)	(0.59)	(21.94)
XII	Profit/(loss) from discontinuing operations	149.12	80.08	65.85	312.30
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	-	-	-	-
XVI	Other Comprehensive Income	149.12	80.08	65.85	312.30
	a.i. Items that will not be reclassified to profit or loss (Net of Tax)		0.28		1.13
	Paid Up Share Capital (Face value of Rs.10/-)	995.05	985.05	935.05	985.05
	Total other Comprehensive Income	-	0.28	-	1.13
XVII	Total Comprehensive Income(XV+XVI)	149.12	80.36	65.85	313.43
XVIII	Earnings per equity share:				
	1)Basic	1.50	0.82	70,424.50	
	2)Diluted	1.17	0.63	70,424.50	

Place: Hyderabad
Dated:13/08/2018

For VIVO BIO TECH

M.KALYAN RAM
WHOLE TIME DIRECTOR
DIN:02012580



Notes

1. The Company has adopted IND AS with effect from 01st April,2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 , prescribed under Section 133 of the Companies Act. 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34.
2. The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 13th August,2018.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
4. The figures of the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of full financial year ended 31st March 2018 and the unaudited published year to date figures up to 31st December 2017 which were subjected to limited review.
5. The Standalone Financial Results are reviewed by the statutory auditors as per Regulation.33 of SEBI(Listing Obligations and disclosure Requirements) Regulations,2015
6. An Extract of the detailed format of unaudited financial results filed with stock exchange under Regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations,2015 will be published in Newspaper.
7. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Place: Hyderabad

Date: 13th August, 2018

For Vivo Bio Tech Limited



M Kalyan Ram

Whole Time Director

DIN: 02012580



PCN & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

To

The Board of Directors
Vivo Bio Tech Limited
Hyderabad

Limited Review Report for the quarter ended 30th June, 2018

1. We have reviewed the accompanying statement of unaudited financial results of M/s. **Vivo Bio Tech Limited** for the quarter ended 30th June, 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 13th August, 2018. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PCN & Associates
Chartered Accountants
FRN: 016016S

Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 13th August 2018